Crane Co

**Signal Note: Driehaus Growth Position in Crane Co (CR)** This $93.3M initiation by a growth-focused biotech allocator is notable given Crane's industrial diversification (fluid handling, aerospace, payment systems) rather than pipeline strength—CR has minimal clinical-stage assets. The timing suggests conviction in either near-term operational/M&A catalysts, aerospace demand tailwinds, or potential strategic repositioning; however, this appears a diversified industrial play rather than a biotech-specific thesis, warranting clarification on Driehaus's investment rationale.